PARK7 and amyotrophic lateral sclerosis: Further studies are needed to verify the ability of this peptide to alter the disease course in vivo, and should be examined in different models of the disease since the results presented herein were obtained in mutated SOD1 model of the disease These results imply that DJ-1 is a possible therapeutic target in ALS(at least with mutated SOD1) and encourage further research on the mechanisms involved in the neuroprotective properties of DJ-1 in this devastating disease.